Welcome
Support Centre
30 September 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Manchester Asthma and Allergy Study
ISRCTN ISRCTN72673620
DOI 10.1186/ISRCTN72673620
ClinicalTrials.gov identifier
EudraCT number
Public title Manchester Asthma and Allergy Study
Scientific title
Acronym MAAS
Serial number at source N/A
Study hypothesis Birth cohort study investigating the development of asthma and allergic disease
Lay summary
Ethics approval Age 0 - 5 years follow up, ERP/94/032, approval received on 24/03/1994. Age 5 - 8 years follow up, SOU/00/258 and SOU/00/259, approval received on 20/12/2000. Age 8 - 11 years follow up, 03/SM/400, approval received on 05/12/03
Study design Prospective, observational, birth cohort study
Countries of recruitment United Kingdom
Disease/condition/study domain Asthma and allergy
Participants - inclusion criteria Children born at Wythenshawe Hospital, Manchester and Stepping Hill Hospital, Stockport between January 1996 and April 1998
Participants - exclusion criteria Premature birth <32 weeks gestation
Anticipated start date 01/09/1995
Anticipated end date 01/06/2019
Status of trial Ongoing
Patient information material
Target number of participants 1250
Interventions This is a prospective, observational birth cohort study, which includes investigating environmental exposures, immune responses, behaviour or family functioning, genetic epidemiology, pulmonary physiology and clinical outcomes
Primary outcome measure(s) 1. Asthma at age 5, 8, 11 and 14 years
2. Sensitisation at age 1, 3, 5, 8, 11 and 14 years
3. Allergies (e.g. hay fever) at age 5, 8, 11 and 14 years
Secondary outcome measure(s) 1. Wheeze and eczema at age 1, 3, 5, 8, 11 and 14 years
2. Healthcare utilisation by age 8 - 11 years
Sources of funding 1. Asthma UK (UK)
2. Moulton Charitable Trust (UK)
Trial website
Publications 1. 2008 results in http://www.ncbi.nlm.nih.gov/pubmed/18356563
2. 2008 results in http://www.ncbi.nlm.nih.gov/pubmed/20167852
Contact name Prof  Adnan  Custovic
  Address North West Lung Research Centre
Wythenshawe Hospital
Southmoor Road
  City/town Manchester
  Zip/Postcode M23 9LT
  Country United Kingdom
  Tel +44 (0)161 291 2494
  Fax +44 (0)161 291 5057
  Email adnan.custovic@manchester.ac.uk
Sponsor Wythenshawe Hospital (UK)
  Address c/o Andrew Maines
Research and Development Directorate
ERC Building
Wythenshawe Hospital
Southmoor Road
  City/town Manchester
  Zip/Postcode M23 9LT
  Country United Kingdom
  Tel +44 (0)161 291 5775
  Fax +44 (0)161 291 5771
  Email andrew.maines@manchester.ac.uk
Date applied 18/04/2006
Last edited 16/07/2010
Date ISRCTN assigned 05/05/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.